The European Commission (EC) approved Vanda Pharmaceuticals Inc’s Hetlioz (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in totally blind adults in the European Union (EU).
“The European approval of Hetlioz is an important milestone for the Non-24 patients throughout the European Union who live with this debilitating disorder,” says Mihael H. Polymeropoulos, MD, Vanda’s president and CEO, in a release.
The marketing authorization allows for the marketing of Hetlioz in all 28 EU member states as well as European Economic Area members Iceland, Liechtenstein, and Norway. The EC has also confirmed orphan drug designation for Hetlioz for the treatment of Non-24 in totally blind adults.
We don’t need another drug. What we need is flex time work solutions and a world that acknowledges that’s it’s perfectly fine to be different. There’s no reason why anyone is seeking to drug Non24’s into fake normalcy. That”normalcy” is ONLY for the convenience of those who are a major waste of planetary resources in that they consume, consume, consume and insanely think they have a right to tell the other 98% of us how to live.